MS ‘Wonder’ Drug: Hopes dashed as trials discover it’s no better than placebo

New multiple sclerosis (MS) ‘wonder’ drug Rituxan doesn’t work, the manufacturer has admitted.  A two-year study has discovered that it is no better than placebo in slowing disability among sufferers with primary progressive MS.

Had it worked, it would have been the third disease that Rituxan is supposed to treat.  It was developed by its manufacturer Genentech and Biogen Idec as a drug for cancer of the blood, but it is now one of the most prescribed drugs for rheumatoid arthritis, with sales in the USA alone of $2.29bn last year.

(Source: New York Times, April 15, 2008).

Related WDDTY Content

Multiple sclerosis - Poisoning in slow motion

Multiple sclerosis (MS) often follows a highly individual and unpredictable course, sometimes leading to chronic and occasionally devastating disabili...

Multiple sclerosis

In orthodox medicine, the current fashion in combating multiple sclerosis (MS) is to administer immune modifiers: interferons 1b and 1a, copolymer 1 a...

Rheumatoid arthritis

In treating rheumatoid arthritis (RA), conventional medicine has concentrated on powerful drugs to suppress symptoms. But there are a surprising numb...

Rheumatoid arthritis

Four years ago (WDDTY, vol 8, no 6) when I first wrote about rheumatoid arthritis (RA), I reported that wearing copper bracelets, correcting low gastr...

Case study: rheumatoid arthritis and HRT

I have had rheumatoid arthritis for more than 10 years. When it was first diagnosed, I was given Indocid, a non-steroidal anti-inflammatory drug. Wh...

Treat depression to slow down multiple sclerosis

New evidence suggests that effective treatment of depression may also slow the progress of multiple sclerosis (MS) in these patients. ...